Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,408.50
(
-1.24%
)
US TECH 100
28,244.40
(
-1.90%
)
Dow Jones
49,526.17
(
-1.07%
)
Brent Oil
108.07
(
0.55%
)
Bitcoin
77,012.62
(
-0.51%
)
News Focus
News Focus
Post# of 257580
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122988
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: biomaven0 post# 144897

Monday, 07/02/2012 1:42:08 PM

Monday, July 02, 2012 1:42:08 PM

Post# of 257580

Too bad MNTA is now wasting their money in the overcrowded oncology space. :)

LOL—apparently you plan to use this soundbite as often as you can :- ) In case some reader didn’t realize you were being facetious, let me note that M402 represents less than 2% of MNTA’s underlying value according to any reasonable analysis I can envision.

In other words, MNTA is not one of the myriad clones of small biotech companies pursuing near-hopeless odds with a cadre of cancer drug candidates.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today